 | • レポートコード：MRC2303M139 • 出版社/出版日：Mordor Intelligence / 2023年1月23日 • レポート形態：英文、PDF、119ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医薬品 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| モルドールインテリジェンス社の本調査資料によると、世界の小児用医薬品市場規模が、予測期間中に年平均成長率4.6%で拡大すると予測されています。本書は、小児用医薬品の世界市場にフォーカスし、最新動向と今後の市場性などをまとめており、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、治療薬別（呼吸器疾患治療薬、自己免疫疾患治療薬、胃腸薬、心血管薬、その他）分析、投与経路別（経口、局所、非経口、その他）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来の動向などが掲載されています。また、PTC Therapeutics Inc.、BioMarin Pharmaceutical Inc.、Horizon Therapeutics PLC、Sumitomo Dainippon Pharma Co. Ltd、Gilead Sciences Inc.、Jazz Pharmaceuticals Inc.、Pfizer Inc.、Glaxosmithkline PLC、Johnson & Johnson、Boehringer Ingelheim International GmbH、Sanofi SA、Novartis AGなど、主要企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の小児用医薬品市場規模：治療薬別 - 呼吸器疾患治療薬の市場規模 - 自己免疫疾患治療薬の市場規模 - 胃腸薬の市場規模 - 心血管薬の市場規模 - その他の市場規模 ・世界の小児用医薬品市場規模：投与経路別 - 経口投与における市場規模 - 局所投与における市場規模 - 非経口投与における市場規模 - その他における市場規模 ・世界の小児用医薬品市場規模：地域別 - 北米の小児用医薬品市場規模 アメリカの小児用医薬品市場規模 カナダの小児用医薬品市場規模 メキシコの小児用医薬品市場規模 … - ヨーロッパの小児用医薬品市場規模 イギリスの小児用医薬品市場規模 フランスの小児用医薬品市場規模 ドイツの小児用医薬品市場規模 … - アジア太平洋の小児用医薬品市場規模 中国の小児用医薬品市場規模 インドの小児用医薬品市場規模 日本の小児用医薬品市場規模 … - 南米/中東の小児用医薬品市場規模 ブラジルの小児用医薬品市場規模 アルゼンチンの小児用医薬品市場規模 南アフリカの小児用医薬品市場規模 … - その他地域の小児用医薬品市場規模 ・競争状況 ・市場機会・将来の動向 |
The pediatric drugs market was anticipated to witness a CAGR of nearly 4.6% during the forecast period.
The COVID-19 pandemic impacted the global pediatric drug market. In the business world, the COVID-19 pandemic has created unprecedented economic uncertainty. While some businesses are relatively insulated due to low exposure, many others have been unable to avoid the pandemic’s effects and are experiencing financial hardship. The COVID-19 pandemic and subsequent public health guidance to reduce the spread of the disease have wide-reaching implications for children’s health and wellbeing. Pediatric emergency departments (EDs) have rapidly adapted the provision of care in response to the pandemic.
The major factors attributing to the growth of the pediatric drugs market are a rise in the birth rate compared to previous years and the increased volume of fatal pediatric cases, which are leading to even deaths due to various diseases, viral infections, GI disorders, lung cancers, and malnutrition. According to the United Nations International Children’s Emergency Fund (UNICEF) 2020 Report, 5.0 million children under five were expected to die by 2020. In 2020, this translated to 13,800 children under five dying each day. Infectious diseases such as pneumonia, diarrhea, and malaria, and preterm birth and intrapartum complications continue to be the leading causes of death among children under the age of five worldwide. Hence, deaths among children under age five demand efficient treatment. The rise in prevalence of renal or pulmonary dysfunctions following hematopoietic stem-cell transplantations (HSCT) due to defective or low immunity results in the growth of the global pediatric drugs market.
Pediatric Drugs Market Trends
Respiratory Disorder Drugs Segment By Indication is Expected to Hold the Major Market Share in the Pediatric Drugs Market
The respiratory disorder drugs segment is expected to account for the largest share of the pediatric drugs market due to lower immunity, increased pollution, and exposure to various allergens, resulting in chronic respiratory disorders such as Chronic obstructive pulmonary disease (COPD). COPD is a major cause of the global pediatric healthcare burden, leading to an increased demand for the efficient treatment of the diseases, in turn fueling the market. According to the World Health Organization 2021, Chronic Obstructive Pulmonary Disease (COPD) was the third leading cause of death worldwide, causing 3.23 million deaths in 2019. Thus, the increasing prevalence of COPD among children is expected to boost the market growth over the forecast period.
On the other hand, the rare autoimmune disorders drugs segment is anticipated to witness the fastest CAGR and dominate the market during the forecast period. The segment’s dominance can be attributed to the increased prevalence of these disorders due to rising coincidences among the patients with various cancers, genetic disorders, and other autoimmune disorders, which provides incentives to assist and encourage the development of drugs for rare diseases. For instance, in May 2019, the Jacobus pharmaceutical company received approval from the US Food and Drug Administration (FDA) under Priority Review and Fast Track designations for its RUZURGI (amifampridine) tablets. Ruzurgi also received orphan drug designation for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in pediatric patients. These prescription drugs’ high cost may also attribute to the fastest growth, propelling the global pediatric drugs market during the forecast period.
North America Dominates the Market and Expected to do Same in the Forecast Period.
North America is expected to dominate the pediatric drugs market due to the rise in the volume of pediatric patient cases with kids suffering from various autoimmune disorders, respiratory disorders, cerebral palsy, and muscular atrophy, along with a steep rise in the adoption of advanced technologies in the US, which holds the major revenue share of the market in North America.
For instance, according to the article published in the JAMA Network in 2020 by Luyu Xie, asthma was one of the world’s most common chronic diseases in children. In the United States, 6 million children (roughly 8% of the population) have been diagnosed with asthma, costing USD 81.9 billion in annual health care costs and resulting in high demand for pediatric drugs.
The launch of new products by key players in the region for pediatric patients, rise in government initiatives to create awareness in people for pediatric medicines, and early approvals with accelerated drug approval initiative by the USFDA to encourage the development of drugs for rare diseases and to decrease the rising pediatric burden are likely to create more opportunities in the market. For instance, in 2020, Veklury (remdesivir), an antiviral medication, was licensed by the US Food and Drug Administration for use in adults and children aged 12 and above.
Also, the rise in disposable income and improvements in healthcare infrastructure are likely to help the global pediatric healthcare market’s growth over the forecast period.
Pediatric Drugs Market Competitor Analysis
The pediatric drugs market is moderately competitive and consists of several major players. A few major players are currently dominating the market in terms of market share. Some prominent players are launching new products to address the unmet challenges in the market, while others are distributing the products. For instance, in April 2019, GSK received approval from the US Food and Drug Administration (FDA) for its intravenous (IV) Benlysta (belimumab), the first medicine approved in the US for children with systemic lupus erythematosus (SLE) from as young as five years of age cranial defects. Some companies currently dominating the market include BioMarin Pharmaceutical Inc., Horizon Therapeutics PLC, Sumitomo Dainippon Pharma Co. Ltd, Gilead Sciences Inc., and Jazz Pharmaceuticals Inc.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market defination
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Burden of Pediatric Diseases such as Diabetes, Respiratory Disorders, and Rise in Affordability with Disposable Income
4.2.2 Increased R&D Activities and Awareness of Pediatric Medicine Among Public
4.3 Market Restraints
4.3.1 Small Size of Study Population and Ethical Issues in Pediatric Research
4.3.2 Risk of Severe Complications Associated with Medicines that may lead to Death
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 Drug Type
5.1.1 Respiratory Disorder Drugs
5.1.2 Autoimmune Disorder Drugs
5.1.3 Gastrointestinal Drugs
5.1.4 Cardiovascular Drugs
5.1.5 Other Drug Types
5.2 Route of Administration
5.2.1 Oral
5.2.2 Topical
5.2.3 Parenteral
5.2.4 Other Routes of Administration
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 PTC Therapeutics Inc.
6.1.2 BioMarin Pharmaceutical Inc.
6.1.3 Horizon Therapeutics PLC
6.1.4 Sumitomo Dainippon Pharma Co. Ltd
6.1.5 Gilead Sciences Inc.
6.1.6 Jazz Pharmaceuticals Inc.
6.1.7 Pfizer Inc.
6.1.8 Glaxosmithkline PLC
6.1.9 Johnson & Johnson
6.1.10 Boehringer Ingelheim International GmbH
6.1.11 Sanofi SA
6.1.12 Novartis AG
7 MARKET OPPORTUNITIES AND FUTURE TRENDS